当前位置:
X-MOL 学术
›
Cancer Discov.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Lorlatinib Is Well Tolerated and Has Activity in ALK+ and ROS1+ NSCLC
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-12-01 , DOI: 10.1158/2159-8290.cd-rw2017-210 American Association for Cancer Research
中文翻译:
洛拉替尼具有良好的耐受性,并在ALK +和ROS1 + NSCLC中具有活性
更新日期:2017-12-05
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-12-01 , DOI: 10.1158/2159-8290.cd-rw2017-210 American Association for Cancer Research
Lorlatinib achieved systemic and intracranial responses in patients with ALK- and ROS1-positive NSCLC.
中文翻译:
洛拉替尼具有良好的耐受性,并在ALK +和ROS1 + NSCLC中具有活性
Lorlatinib在ALK和ROS1阳性的NSCLC患者中获得了全身和颅内反应。